Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

NCT: NCT05731700 · COMPLETED

NCT IDNCT05731700
StatusCOMPLETED
Start Date2021-10-20
Completion2025-05-08

Brief Summary

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

Frequently Asked Questions

What is CVT-ISR First in Human Trial for Coronary In-Stent Restenosis?

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis is a clinical trial registered under NCT05731700. Current status: COMPLETED.

What is the status of NCT05731700?

The current status of NCT05731700 (CVT-ISR First in Human Trial for Coronary In-Stent Restenosis) is: COMPLETED.

When did CVT-ISR First in Human Trial for Coronary In-Stent Restenosis start?

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis started on 2021-10-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑